SENTI BIOSCIENCES INC (SNTI)
US81726A1007 - Common Stock
SNTI gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. While SNTI seems to be doing ok healthwise, there are quite some concerns on its profitability. SNTI is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SNTI has reported negative net income.
SNTI had a negative operating cash flow in the past year.
In the past 5 years SNTI always reported negative net income.
In the past 5 years SNTI always reported negative operating cash flow.
1.2 Ratios
SNTI has a Return On Assets of -59.47%. This is comparable to the rest of the industry: SNTI outperforms 41.61% of its industry peers.
The Return On Equity of SNTI (-106.19%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -59.47% | ||
| ROE | -106.19% | ||
| ROIC | N/A |
ROA(3y)-49.62%
ROA(5y)-49.82%
ROE(3y)-81.17%
ROE(5y)-85.07%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SNTI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SNTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
SNTI has more shares outstanding than it did 1 year ago.
SNTI has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -4.21, we must say that SNTI is in the distress zone and has some risk of bankruptcy.
SNTI's Altman-Z score of -4.21 is on the low side compared to the rest of the industry. SNTI is outperformed by 60.96% of its industry peers.
There is no outstanding debt for SNTI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.21 |
ROIC/WACCN/A
WACC9.27%
2.3 Liquidity
SNTI has a Current Ratio of 5.62. This indicates that SNTI is financially healthy and has no problem in meeting its short term obligations.
SNTI's Current ratio of 5.62 is in line compared to the rest of the industry. SNTI outperforms 59.59% of its industry peers.
SNTI has a Quick Ratio of 5.62. This indicates that SNTI is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.62, SNTI is in the better half of the industry, outperforming 60.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.62 | ||
| Quick Ratio | 5.62 |
3. Growth
3.1 Past
SNTI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -20.34%.
Looking at the last year, SNTI shows a very negative growth in Revenue. The Revenue has decreased by -40.09% in the last year.
Measured over the past years, SNTI shows a very strong growth in Revenue. The Revenue has been growing by 65.01% on average per year.
EPS 1Y (TTM)-20.34%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-4.61%
Revenue 1Y (TTM)-40.09%
Revenue growth 3Y65.01%
Revenue growth 5YN/A
Revenue growth Q2Q-100%
3.2 Future
SNTI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.01% yearly.
Based on estimates for the next years, SNTI will show a very strong growth in Revenue. The Revenue will grow by 67.25% on average per year.
EPS Next Y50.76%
EPS Next 2Y36.01%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year286.96%
Revenue Next 2Y223.03%
Revenue Next 3Y18.22%
Revenue Next 5Y67.25%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SNTI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNTI. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SNTI's earnings are expected to grow with 36.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.01%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for SNTI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SENTI BIOSCIENCES INC
NASDAQ:SNTI (4/25/2024, 7:18:01 PM)
After market: 0.2787 0 (0%)0.2787
0 (-0.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap12.75M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -59.47% | ||
| ROE | -106.19% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.62 | ||
| Quick Ratio | 5.62 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-20.34%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y50.76%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-40.09%
Revenue growth 3Y65.01%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y